Live Roundups Editor's Desk Insights Executive Ops Weather About 🔍
Home › Business & Finance › AI Is 'Accelerant' For Clients, Says S&P Global CFO
Business & Finance

AI Is 'Accelerant' For Clients, Says S&P Global CFO

Bloomberg Technology Thursday 27 August 2026, 19:52 UTC 1 min read
Key Points

Eric Aboaf, CFO of S&P Global, said that his business is to create transparency around hyperscalers for investors as the AI buildout shows no signs of slowing down. Aboaf, who was joined by Bloomberg's Nina Trentmann, said that AI is also an 'accelerant' for S&P Global on the client and revenue side of the business, as feature to help clients access key data.

Eric Aboaf, CFO of S&P Global, said that his business is to create transparency around hyperscalers for investors as the AI buildout shows no signs of slowing down. Aboaf, who was joined by Bloomberg's Nina Trentmann, said that AI is also an 'accelerant' for S&P Global on the client and revenue side of the business, as feature to help clients access key data. (Source: Bloomberg)
AI (ORG) S&P Global (ORG) Eric Aboaf (PERSON) CFO (ORG) S&P Global (ORG) Aboaf (ORG) Bloomberg (ORG) Nina Trentmann (PERSON)
Originally published by Bloomberg Technology Read original →

Related Stories

Clean-up of illegal waste supersite costs taxpayers £6m

The bill for clearing the dump in Oxfordshire has been covered by taxpayers.

BBC Science 4m ago

Clean-up of illegal waste supersite costs taxpayers £6m

The bill for clearing the dump in Oxfordshire has been covered by taxpayers.

BBC Science 4m ago

LIV Golf: From Disruptor to Distressed Asset

The era of the sovereign blank check is over. When LIV Golf launched in 2022, it was defined not by its roster, but by the bottomless liquidity of Saudi Arabia’s Public Investment Fund (PIF). That capital was a weapon used to force a hostile market disruption, but when the sovereign mandate shifted, the fuel for that engine evaporated.

Bloomberg Markets 4m ago

RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year

Revolution Medicines won US approval for a breakthrough pill that lengthens the lives of patients with advanced pancreatic cancer, a major advance against one of the hardest-to-treat tumor types. The once-daily drug carries a list price of more than $475,000 a year, making it one of the most expensive cancer treatments in history. The company branded it Rasonque and made it available starting Wednesday.

Bloomberg Markets 8m ago